Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.39 |
| ▸ | CTSL | P07711 | 10/20 | 0.39 |
| ▸ | CTSS | P25774 | 7/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4390158 | 1.00 | CTSK (0.39) | CTSKCTSLCTSSCTSBCACNA1B | |
| SCHEMBL13588919 | 0.97 | CTSK (0.39) | CTSKCTSLCTSSCTSBCACNA1B | |
| SCHEMBL13588914 | 0.89 | CTSK (0.48) | CTSKCTSLCTSSCTSBCACNA1B | |
| Hydrochloric Acid SCHEMBL4379491 | 0.88 | CTSK (0.49) | CTSKCTSLCTSSCTSBCACNA1B | |
| Hydrochloric Acid SCHEMBL4379488 | 0.88 | CTSK (0.49) | CTSKCTSLCTSSCTSBCACNA1B | |
| Oxalic Acid SCHEMBL4381733 | 0.87 | CTSK (0.36) | CTSKCTSLCTSSCTSBCACNA1B | |
| Oxalic Acid SCHEMBL4381726 | 0.87 | CTSK (0.36) | CTSKCTSLCTSSCTSBCACNA1B | |
| SCHEMBL13588915 | 0.85 | LMNA (0.44) | CTSKCTSLCTSSCTSBCACNA1B | |
| SCHEMBL13588918 | 0.85 | CYP2C19 (0.44) | CTSKCTSLCTSSCTSB | |
| Hydrochloric Acid SCHEMBL4379030 | 0.84 | LMNA (0.44) | CTSKCTSLCTSSCTSBCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | CTSK 3322/4885CTSL 2813/4885CTSS 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.